BHC
$5.18
Bausch Health Companies Inc.
Recent News
Should Bausch Health’s Profit Return and 2026 Outlook Shift the Investment Case for BHC?
Bausch Health Companies recently reported fourth-quarter 2025 revenue of US$2,796 million and a net loss of US$112 million, alongside full-year 2025 revenue of US$10.27 billion and net income of US$157 million, while also recording a US$145 million goodwill impairment and issuing 2026 revenue guidance of US$10.63–US$10.88 billion. Against this backdrop, Bausch and its OraPharma dental unit marked the 25th anniversary of ARESTIN®, the only FDA-approved locally applied antibiotic adjunct for...
Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook
Bausch Health Companies Inc. (NYSE:BHC) is among the 7 Oversold Pharma Stocks to Buy Now. Bausch Health Companies Inc. (NYSE:BHC) is one of the most oversold stocks. TheFly reported on February 19 that Bank of America raised its price target for Bausch + Lomb (BLCO) to $15 from $13 and kept an Underperform rating. The […]
Bausch Health Weighs China Aesthetics Push Against ARESTIN Milestone And Debt
Bausch Health Companies (NYSE:BHC) agreed to acquire Shibo's aesthetics distribution business in China, expanding its presence in that market. The company marked the 25th anniversary of its ARESTIN® product, highlighting its long-running role in the portfolio. ARESTIN® has been introduced into additional markets, including Canada and Puerto Rico, alongside adjustments to Bausch Health's capital structure. Bausch Health Companies, listed as NYSE:BHC, operates across eye health,...
Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.
BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth
Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.